Investigating Genetic Status in Patients Presenting to Clinic

Condition(s) studied

Investigational drug(s) / intervention(s)

Biosample collection.: Blood draw.

Study summary

The causes of neurodegenerative dementias such as Frontotemporal Dementia, Lewy Body Disease and Alzheimer's disease are still largely unknown. While the contribution of some genetic mutations and polymorphisms is associated with autosomal dominant patterns of inheritance of these dementias, in many cases, the specific causative mutation in these families is not yet identified. Further, in many patients, polygenic risk is thought to give rise to pathophysiologic changes, but which specific genes affect risk are largely yet unknown. By examining genotypes in patients that present to our Cognitive Neurology and Alzheimer's Research Clinic with suspected or confirmed neurodegenerative dementia, or have a history of a familial dementia, we aim to help identify and characterize genetic mutations or polymorphisms that give rise to neurodegenerative diseases.

Eligibility

Primary outcome measure(s)

• Blood draw for genetic status or polymorphism result. — A one-time visit, taking the participant approximately 20 minutes total for all study procedures.
  The blood draw is taken at the time of the clinic visit. Up to 30ml will be collected by standard venipuncture.

Trial sites (1)

More London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials in Canada

Other trials for the same condition